Neumora Therapeutics, Inc. (NMRA)
0.3672
-0.02
(-5.43%)
USD |
NASDAQ |
Oct 30, 16:00
0.3673
0.00 (0.00%)
After-Hours: 20:00
Neumora Therapeutics Enterprise Value : 5.030M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 5.030M |
| October 29, 2026 | 8.972M |
| October 28, 2026 | 9.869M |
| October 27, 2026 | 5.198M |
| October 26, 2026 | 9.832M |
| October 23, 2026 | 7.309M |
| October 22, 2026 | 12.22M |
| October 21, 2026 | 14.15M |
| October 20, 2026 | 23.30M |
| October 19, 2026 | 24.24M |
| October 16, 2026 | 24.95M |
| October 15, 2026 | 16.20M |
| October 14, 2026 | 2.657M |
| October 13, 2026 | 5.590M |
| October 12, 2026 | 18.13M |
| October 09, 2026 | 25.30M |
| October 08, 2026 | 26.07M |
| October 07, 2026 | 23.92M |
| October 06, 2026 | 24.42M |
| October 05, 2026 | 34.57M |
| October 02, 2026 | 29.82M |
| October 01, 2026 | 39.19M |
| September 30, 2026 | 47.82M |
| September 29, 2026 | 63.03M |
| September 28, 2026 | 65.68M |
| Date | Value |
|---|---|
| September 25, 2026 | 63.03M |
| September 24, 2026 | 67.79M |
| September 23, 2026 | 73.06M |
| September 22, 2026 | 81.88M |
| September 21, 2026 | 65.68M |
| September 18, 2026 | 72.82M |
| September 17, 2026 | 76.56M |
| September 16, 2026 | 80.89M |
| September 15, 2026 | 91.75M |
| September 14, 2026 | 123.16M |
| September 11, 2026 | 130.74M |
| September 10, 2026 | 149.43M |
| September 09, 2026 | 160.64M |
| September 08, 2026 | 169.98M |
| September 04, 2026 | 181.19M |
| September 03, 2026 | 188.67M |
| September 02, 2026 | 194.27M |
| September 01, 2026 | 184.93M |
| August 31, 2026 | 184.93M |
| August 28, 2026 | 196.14M |
| August 27, 2026 | 212.96M |
| August 26, 2026 | 227.91M |
| August 25, 2026 | 216.69M |
| August 24, 2026 | 221.37M |
| August 21, 2026 | 240.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | -128.50M |
| Context Therapeutics, Inc. | -25.37M |
| LENZ Therapeutics, Inc. | -101.48M |
| BioAge Labs, Inc. | -47.20M |
| ANI Pharmaceuticals, Inc. | 1.889B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.08M |
| Total Expenses (Quarterly) | 43.08M |
| EPS Diluted (Quarterly) | -0.2327 |
| Earnings Yield | -335.9% |
| Normalized Earnings Yield | -329.98 |